Extracellular vesicles in atherothrombosis: From biomarkers and precision medicine to therapeutic targets

L Badimon, T Padro, G Arderiu, G Vilahur… - Immunological …, 2022 - Wiley Online Library
Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of global
mortality. Extracellular vesicles (EVs) are small phospholipid vesicles that convey molecular …

Extracellular vesicles as drivers of immunoinflammation in atherothrombosis

R Suades, MF Greco, T Padró, L Badimon - Cells, 2022 - mdpi.com
Atherosclerotic cardiovascular disease is the leading cause of morbidity and mortality all
over the world. Extracellular vesicles (EVs), small lipid-bilayer membrane vesicles released …

Microvesicles in atherosclerosis and angiogenesis: from bench to bedside and reverse

L Badimon, R Suades, G Arderiu, E Peña… - Frontiers in …, 2017 - frontiersin.org
Atherosclerosis (AT) is a progressive chronic disease involving lipid accumulation, fibrosis,
and inflammation in medium and large-sized arteries, and it is the main cause of …

Extracellular vesicles as new pharmacological targets to treat atherosclerosis

M Yin, X Loyer, CM Boulanger - European journal of pharmacology, 2015 - Elsevier
Extracellular vesicles released by most cell types, include apoptotic bodies (ABs),
microvesicles (MVs) and exosomes. They play a crucial role in physiology and pathology …

Microparticles as potential biomarkers of cardiovascular disease

CN França, MCO Izar, JB Amaral, DM Tegani… - Arquivos Brasileiros …, 2015 - SciELO Brasil
Primary prevention of cardiovascular disease is a choice of great relevance because of its
impact on health. Some biomarkers, such as microparticles derived from different cell …

Therapeutic and pharmacological applications of extracellular vesicles and lipoproteins

K Németh, BM Kestecher, S Ghosal… - British Journal of …, 2024 - Wiley Online Library
In recent years, various approaches have been undertaken to eliminate lipoproteins co‐
isolated with extracellular vesicles, as they were initially regarded as contaminating entities …

The impact of vascular disease treatment on platelet-derived microvesicles

J Rosińska, M Łukasik, W Kozubski - Cardiovascular Drugs and Therapy, 2017 - Springer
Platelet-derived microvesicles (pMVs) are small, heterogeneous vesicles released from
platelet membranes as a result of activation. These microvesicles possess a wide range of …

Endothelial progenitor cells (EPCs) in ageing and age-related diseases: how currently available treatment modalities affect EPC biology, atherosclerosis, and …

V Altabas, K Altabas, L Kirigin - Mechanisms of ageing and development, 2016 - Elsevier
Endothelial progenitor cells (EPCs) are mononuclear cells that circulate in the blood and are
derived from different tissues, expressing cell surface markers that are similar to mature …

The role of blood-borne microparticles in inflammation and hemostasis

R Suades, T Padro, L Badimon - Seminars in thrombosis and …, 2015 - thieme-connect.com
Inflammation has a pivotal role in cardiovascular disease because it contributes to the
progression of atherosclerosis, a chronic inflammatory disease of the vessel wall …

[HTML][HTML] Effect of ezetimibe added to high-intensity statin therapy on low-density lipoprotein cholesterol levels: a meta-analysis

J Lee, U Egolum, H Parihar, M Cooley… - Cardiology …, 2021 - ncbi.nlm.nih.gov
Background Adding ezetimibe to high-intensity statin therapy is used for additional lowering
of low-density lipoprotein cholesterol (LDL-C); however, there are little data on the efficacy of …